At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 21 enrolled
Drug / intervention
Dalantercept plus sorafenibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b, Open Label Study of Dalantercept Plus Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA·interventional·Posted Dec 31, 2013·Updated Sep 26, 2022
In Brief
A Phase 2 clinical trial evaluating Dalantercept plus sorafenib for Advanced Adult Hepatocellular Carcinoma. Completed, enrolled 21 participants across 7 sites.
Detailed Summary
The purpose of this study is to evaluate the safety and tolerability of dalantercept plus sorafenib in patients with advanced hepatocellular carcinoma (HCC) to determine the recommended dose level of dalantercept in combination with sorafenib.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Adult Hepatocellular Carcinoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedDec 2013
Enrollment StartAug 2014
Primary CompletionJul 2017
Study CompletionSep 2017
TodayJul 2026
First PostedDec 31, 2013
Enrollment StartAug 4, 2014
Primary CompletionJul 5, 2017
Study CompletionSep 22, 2017
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 12.5 years ago
Interventions
Dalantercept plus sorafenibdrug
Subcutaneous (SC) injection of dalantercept once every 3 weeks and oral sorafenib daily.